Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

May 10, 2021May 10, 2021

Potential PAH Therapy Identified by Cellular Screen of Thousands

News, PAH News

By screening thousands of potential candidates, researchers have identified a compound, called AG1296, that may be useful for the treatment of pulmonary arterial hypertension (PAH). Their findings were published in the ... Read more

May 3, 2021May 3, 2021

AHR Protein Plays Key Role in PAH Development, May Be Therapy Target

News, PAH News

Activation of a protein called aryl hydrocarbon receptor (AHR) is essential for the development of pulmonary arterial hypertension (PAH), a study found. The findings imply that targeting AHR could be ... Read more

April 16, 2021April 16, 2021

Fungus Used in Chinese Medicine Eased PAH Damage in Rat Model

News, PAH News

Treatment with a fungus called Ophiocordyceps sinensis eased disease signs and improved survival in a rat model of pulmonary arterial hypertension (PAH), suggesting a potential to treat patients. The findings ... Read more

April 14, 2021April 14, 2021

Levosimendan Shows Benefits in 84% of Patients in Small PH-HFpEF Trial

News, PH News

Treatment with the investigational medication levosimendan was found to improve exercise tolerance, and some parameters related to heart function, in a small clinical trial of people with pulmonary hypertension and heart ... Read more

March 22, 2021March 22, 2021

Live Expert Panel to Discuss COVID-19’s Effect on Respiratory Diseases

News

Experts will discuss how the COVID-19 pandemic has affected people living with pulmonary hypertension and other rare respiratory diseases during a live panel discussion this week. The event, taking place ... Read more

March 19, 2021March 19, 2021

Severe COVID-19 Infection Can Lead to Acute PH, Raising Risk of Death

News, PH News

Acute pulmonary hypertension (aPH) is frequent and linked with a higher risk of mortality in people who are severely ill with COVID-19, according to a Swedish study. The study, “Acute pulmonary ... Read more

February 17, 2021February 17, 2021

More Barriers, Lower Socioeconomic Status Tied to Less Exercise Therapy

News

People with pulmonary hypertension are less likely to be referred to exercise therapy if they are of lower socioeconomic status or perceive more barriers to accessing such therapy, a study ... Read more

February 3, 2021February 3, 2021

Pemziviptadil Shows Promise in Small Clinical Trial

News, PAH News

PhaseBio Pharmaceuticals‘s investigational therapy pemziviptadil (PB1046) showed a good safety profile and clinically meaningful effects on physical function in a small clinical trial of three people with pulmonary arterial hypertension ... Read more

December 18, 2020December 18, 2020

Sotatercept Receives Orphan Drug Designation in Europe

News, PAH News

The European Commission has granted orphan drug designation to sotatercept for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications with the potential to ... Read more

November 18, 2020November 20, 2020

Phase 2b Trial of Pemziviptadil, Peptide Treatment for PAH, Enrolling in US

News, PAH News

Enrollment is resuming for the VIP clinical trial, which is evaluating PhaseBio Pharmaceuticals‘ investigational therapy pemziviptadil (PB1046) in people with pulmonary arterial hypertension (PAH). The trial, which is recruiting adult patients ... Read more